Hunan Dajiahui Pharmaceutical Industry Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions. Recently, the Company's wholly-owned subsidiary, Dajiahui Biopharmaceutical Co., Ltd., received the "Drug Registration Certificate" for Azithromycin Dry Suspension approved and issued by the National Medical Products Administration. The relevant information is announced as follows:
301126SZSE
Announcement on Obtaining the Drug Registration Certificate for Azithromycin Dry Suspension
✨ AI Summary
Hunan Dajiahui Pharmaceutical Industry Co., Ltd. announced that its wholly-owned subsidiary received a drug registration certificate for Azithromycin Dry Suspension from the National Medical Products Administration. The product is classified as a chemical drug and is approved for various bacterial infections. This approval enhances the company's product portfolio and core competitiveness, although production and sales remain subject to market uncertainties.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.